* 2025 to end on a soft note * We cut '26e-'27e adj.
* Omsättning under förväntan men förbättrade marginaler * USA-närvaron stärks i flera led * Vi behål...
Suominen’s challenges continue at least in the short-term, but the company is now taking more signif...
VNV Global stänger året med en investeringsportfölj om 537,5 musd (−16,5% YoY) efter avyttringar av ...
Redeye provides its initial take on Lifco’s Q4 2025 report, which missed our projections by 3% on sa...
* Adj. EBIT 29% above estimates at SEK 47m * '26e could bring both organic and structural growth * C...
Redeye comments on Enea’s Q4 2025 report were sales fell short of expectations, yet profitability ex...
Redeye comments on Freemelt ahead of Q4 and full year results.
Smart Eye has reached a key milestone by being selected by a Japanese OEM to supply DMS software inc...
In Q4/25, we see similar trends impacting NAV as in previous quarters: listed peers trading down and...
Scanfil's guidance for 2026 indicates net sales growth of 16-31% we calculate.
Our revisions are material, as we remove the US contribution from the Zimmer Biomet deal, given that...
Redeye comments on Magle’s strategic pivot toward profitability, operational discipline, and sustain...
Redeye comments on the news that Egetis has completed its rolling NDA submission for Emcitate in the...
Suominen Q4 comparable EBITDA of EUR 1.9m came 60% below Vara Research consensus expectations.
Redeye provides its initial take on Indutrade’s Q4 2025 report, which missed on earnings, mainly due...
Redeye comments on q.beyond’s preliminary Q4 figures, showing stronger EBITDA than expected.
VNV reported a Q4 NAV per share which is down 8% q/q in SEK terms and the company ended the year wit...
Physitrack released preliminary Q4 2025 figures this morning, which were broadly in line with our ex...
We raise adjusted EBITA by 2% for 2026E-27E, following the stronger-than-expected profitability in Q...
